Key Financial Data
| Key Data | Net Sales |
| Sales by Business | Pharmaceuticals: Net Sales |
| Key P&L and Cash Flow | Balance Sheet Structure |
| Per Share Data | |
Key Data
| (m €) | ||||||
|---|---|---|---|---|---|---|
| 2007 | 2008 | 2009 | 2010 | 2011 | ||
| Net Sales | 628.4 (100%) |
689.6 (100%) |
747.5 (100%) |
728.1 (100%) |
762.0 (100%) | |
| Operating Income | 131.5 (20.9%) |
144.7 (21.0%) |
162.2 (21.7%) |
154.8 (21.3%) |
163.5 (21.5%) | |
| Net Income | 84.9 (13.5%) |
100.4 (14.6%) |
110.6 (14.8%) |
108.6 (14.9%) |
116.4 (15.3%) | |
Net Sales
Sales by Business
Pharmaceuticals: Net Sales
Key P&L and Cash Flow
| (m €) | ||||||
|---|---|---|---|---|---|---|
| 2007 | 2008 | 2009 | 2010 | 2011 | ||
| Net Sales | 628.4 | 689.6 | 747.5 | 728.1 | 762.0 | |
| Gross profit as % of Sales |
422.1 67.2% |
467.4 67.8% |
511.9 68.5% |
488.1 67.0% |
502.1 65.9% | |
| Operating Income (EBIT) as % of Sales |
131.5 20.9% |
144.7 21.0% |
162.2 21.7% |
154.8 21.3% |
163.5 21.5% | |
| Pretax Income | 127.4 | 138.1 | 152.7 | 151.0 | 160.0 | |
| Net Income | 84.9 | 100.4 | 110.6 | 108.6 | 116.4 | |
| CASH FLOW | 113.7 | 140.3 | 149.2 | 135.8 | 140.7 | |
Balance Sheet Structure
Per Share Data
| 2007 | 2008 | 2009 | 2010 | 2011 | |
| Earnings per share (EPS) | 0.427 | 0.511 | 0.561 | 0.548 | 0.584 |
|---|---|---|---|---|---|
| Shareholders'equity per share | 1.989 | 2.262 | 2.575 | 2.896 | 2.982 |
| Dividend for share | 0.215 | 0.250 | 0.275 | 0.275 | 0.30 |
